The Latest U.S.-China Tit-For-Tat… And Fast Money’s Obesity Week Continues 12/3/24
CNBC's "Fast Money"
00:00
Pemviditutide: A New Frontier in Obesity Treatment
This chapter explores the dual-action obesity drug pemviditutide, which is entering phase three trials with 5,000 subjects. It focuses on the drug's benefits in appetite suppression, energy expenditure, and preservation of lean muscle mass, particularly in older adults. Additionally, the chapter discusses commercialization strategies and the implications of current financial trends in the private credit and cryptocurrency markets.
Play episode from 33:21
Transcript
